MX2009011749A - Compuestos triciclicos como inhibidores de metaloproteinasa matricial. - Google Patents
Compuestos triciclicos como inhibidores de metaloproteinasa matricial.Info
- Publication number
- MX2009011749A MX2009011749A MX2009011749A MX2009011749A MX2009011749A MX 2009011749 A MX2009011749 A MX 2009011749A MX 2009011749 A MX2009011749 A MX 2009011749A MX 2009011749 A MX2009011749 A MX 2009011749A MX 2009011749 A MX2009011749 A MX 2009011749A
- Authority
- MX
- Mexico
- Prior art keywords
- matrix metalloproteinase
- metalloproteinase inhibitors
- tricyclic compounds
- compounds
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 abstract 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92756307P | 2007-05-04 | 2007-05-04 | |
| PCT/US2008/062593 WO2008137816A2 (en) | 2007-05-04 | 2008-05-05 | Tricyclic compounds as matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011749A true MX2009011749A (es) | 2009-11-11 |
Family
ID=39944224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011749A MX2009011749A (es) | 2007-05-04 | 2008-05-05 | Compuestos triciclicos como inhibidores de metaloproteinasa matricial. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100227859A1 (OSRAM) |
| EP (1) | EP2144893A2 (OSRAM) |
| JP (1) | JP2010526106A (OSRAM) |
| AR (1) | AR066412A1 (OSRAM) |
| CA (1) | CA2685389A1 (OSRAM) |
| CL (1) | CL2008001257A1 (OSRAM) |
| MX (1) | MX2009011749A (OSRAM) |
| PA (1) | PA8779101A1 (OSRAM) |
| PE (1) | PE20090223A1 (OSRAM) |
| TW (1) | TW200900397A (OSRAM) |
| WO (1) | WO2008137816A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE517106T1 (de) * | 2006-02-22 | 2011-08-15 | Vertex Pharma | Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren |
| US9273021B2 (en) | 2009-02-05 | 2016-03-01 | Trustees Of Boston College | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof |
| WO2010117932A1 (en) * | 2009-04-06 | 2010-10-14 | Schering Corporation | Indole derivatives and methods for antiviral treatment |
| CN104995559B (zh) | 2013-02-08 | 2020-04-07 | 三菱瓦斯化学株式会社 | 抗蚀剂组合物、抗蚀图案形成方法和用于其的多元酚衍生物 |
| CN105377851B (zh) * | 2013-03-11 | 2018-07-20 | 密执安州立大学董事会 | Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法 |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| SG11201705038XA (en) | 2014-12-25 | 2017-07-28 | Mitsubishi Gas Chemical Co | Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method |
| US11256170B2 (en) | 2015-03-31 | 2022-02-22 | Mitsubishi Gas Chemical Company, Inc. | Compound, resist composition, and method for forming resist pattern using it |
| WO2016158169A1 (ja) | 2015-03-31 | 2016-10-06 | 三菱瓦斯化学株式会社 | レジスト組成物、レジストパターン形成方法、及びそれに用いるポリフェノール化合物 |
| EP3346335A4 (en) | 2015-08-31 | 2019-06-26 | Mitsubishi Gas Chemical Company, Inc. | MATERIAL FOR FORMING LITHOGRAPHY OF LAYER LAYERS, COMPOSITION FOR FORMING LITHOGRAPHY LAYER LAYERS, LITHOGRAPHY LAYERINGS AND METHOD FOR THE PRODUCTION THEREOF, PATTERN FORMULATION, RESIN AND CLEANING METHOD |
| JP7020912B2 (ja) | 2015-08-31 | 2022-02-16 | 三菱瓦斯化学株式会社 | リソグラフィー用下層膜形成材料、リソグラフィー用下層膜形成用組成物、リソグラフィー用下層膜及びその製造方法、並びにレジストパターン形成方法 |
| CN108137478B (zh) | 2015-09-10 | 2021-09-28 | 三菱瓦斯化学株式会社 | 化合物、其组合物、纯化方法以及抗蚀图案形成方法、非晶膜的制造方法 |
| US10042251B2 (en) | 2016-09-30 | 2018-08-07 | Rohm And Haas Electronic Materials Llc | Zwitterionic photo-destroyable quenchers |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| KR102435507B1 (ko) * | 2019-07-31 | 2022-08-24 | 일동제약(주) | 신규 벤조퓨란 유도체 및 이의 용도 |
| CN113929645B (zh) * | 2021-12-15 | 2022-03-11 | 长沙普济生物科技股份有限公司 | 一种光催化合成苯并呋喃基氨基酸表面活性剂的方法 |
| CN117045635A (zh) * | 2022-05-13 | 2023-11-14 | 中国海洋大学 | 一种3-苯基二苯并呋喃类化合物在药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2256716A1 (en) * | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
| KR20000068415A (ko) * | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 |
| TR200202211T2 (tr) * | 1999-08-18 | 2002-11-21 | Warner-Lambert Company | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
| MXPA01013172A (es) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US20030157110A1 (en) * | 2002-01-07 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
| CA2667644A1 (en) * | 2006-10-27 | 2008-05-15 | Wyeth | Tricyclic compounds as matrix metalloproteinase inhibitors |
-
2008
- 2008-04-30 PE PE2008000773A patent/PE20090223A1/es not_active Application Discontinuation
- 2008-04-30 PA PA20088779101A patent/PA8779101A1/es unknown
- 2008-04-30 AR ARP080101855A patent/AR066412A1/es unknown
- 2008-04-30 CL CL200801257A patent/CL2008001257A1/es unknown
- 2008-05-05 CA CA002685389A patent/CA2685389A1/en not_active Abandoned
- 2008-05-05 JP JP2010506709A patent/JP2010526106A/ja not_active Withdrawn
- 2008-05-05 US US12/598,868 patent/US20100227859A1/en not_active Abandoned
- 2008-05-05 MX MX2009011749A patent/MX2009011749A/es not_active Application Discontinuation
- 2008-05-05 TW TW097116522A patent/TW200900397A/zh unknown
- 2008-05-05 WO PCT/US2008/062593 patent/WO2008137816A2/en not_active Ceased
- 2008-05-05 EP EP08755041A patent/EP2144893A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001257A1 (es) | 2008-07-04 |
| WO2008137816A8 (en) | 2010-01-28 |
| WO2008137816A2 (en) | 2008-11-13 |
| US20100227859A1 (en) | 2010-09-09 |
| JP2010526106A (ja) | 2010-07-29 |
| TW200900397A (en) | 2009-01-01 |
| EP2144893A2 (en) | 2010-01-20 |
| PA8779101A1 (es) | 2008-12-18 |
| CA2685389A1 (en) | 2008-11-13 |
| WO2008137816A3 (en) | 2009-05-14 |
| PE20090223A1 (es) | 2009-03-08 |
| AR066412A1 (es) | 2009-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011749A (es) | Compuestos triciclicos como inhibidores de metaloproteinasa matricial. | |
| SG10201809895YA (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
| PH12020550759A1 (en) | Compositions and methods of use of phorbol esters | |
| NZ595705A (en) | Protease inhibitors | |
| TN2011000339A1 (en) | Poly (adp-ribose) polymerase (parp) inhibitors | |
| MA33776B1 (fr) | Dérivés arylecarbonyle et hétéroarylcarbonyle d'hexahydroindénopyridine et d'octahydrobenzoquinoline | |
| IL198116A0 (en) | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors | |
| MX2010007714A (es) | Piridinas fusionadas activas como inhibidores de c-met. | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| PH12012500903A1 (en) | N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| IN2012DN03337A (OSRAM) | ||
| TW200738241A (en) | Pyridazine derivatives | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| MX2010010502A (es) | Inhibidores de desacetilasas b a base de hidroxamato. | |
| IN2012DN00765A (OSRAM) | ||
| GEP20125389B (en) | Substituted pyrazole and triazole compounds as ksp inhibitors | |
| BRPI0511433A (pt) | derivados de quinolina substituìda como inibidores de cinesina mitótica | |
| IN2012DN03846A (OSRAM) | ||
| WO2009076602A8 (en) | 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors | |
| MY147188A (en) | Substituted imidazole compounds as ksp inhibitors | |
| EA201100350A1 (ru) | Противогрибковые средства | |
| TN2010000428A1 (en) | Hydroxamate - based inhibitors of deacetylases b | |
| HK1179117A (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |